Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)
Status:
Unknown status
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to investigate whether oral treatment of patients
suffering from cutaneous T cell lymphoma with dimethylfumarate is leading to a significant
improvement of modified severity assessment tool (mSWAT) values in the skin after 24 weeks of
treatment (primary endpoint). Secondary endpoints will be CTCL severity index, dermatologic
life quality index, itching measured by a VAS and the blood involvement if applicable.
Primary: safety and efficacy of DMF treatment in CTCL Secondary: CTCL severity index,
Dermatologic Life Quality index, VAS for itching, blood involvement if appl.
Phase:
Phase 2
Details
Lead Sponsor:
Universitätsmedizin Mannheim
Collaborators:
KKS Netzwerk Klinikum Krefeld Klinikum Ludwigshafen Klinikum Minden Universitätsklinikum Kiel Wuerzburg University Hospital